Immediate Impact
3 from Science/Nature 51 standout
Citing Papers
The present and future of bispecific antibodies for cancer therapy
2024 Standout
Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2– and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study
2024 Standout
Works of Jon Greenberg being referenced
First-in-Human, Phase I Dose-Escalation and Dose-Expansion Study of Trophoblast Cell-Surface Antigen 2–Directed Antibody-Drug Conjugate Datopotamab Deruxtecan in Non–Small-Cell Lung Cancer: TROPION-PanTumor01
2023
A randomized, double-blind, placebo-controlled phase 2 study of tigatuzumab (CS-1008) in combination with carboplatin/paclitaxel in patients with chemotherapy-naïve metastatic/unresectable non-small cell lung cancer
2013
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Jon Greenberg | 53 | 96 | 105 | 81 | 12 | 299 | |
| Ting‐Yu Lin | 16 | 172 | 61 | 21 | 17 | 295 | |
| Jean Ferguson Carr | 31 | 91 | 50 | 34 | 18 | 294 | |
| Shigeharu Kimura | 40 | 80 | 124 | 28 | 11 | 287 | |
| Isabelle Goddard | 55 | 137 | 49 | 67 | 16 | 317 | |
| Gabriele Leder | 9 | 145 | 56 | 66 | 12 | 311 | |
| Maribel Lara‐Chica | 8 | 166 | 60 | 52 | 13 | 288 | |
| Amelia Karlsson | 8 | 176 | 45 | 27 | 11 | 315 | |
| Brooke C. Matson | 12 | 138 | 42 | 63 | 14 | 280 | |
| Soo Min | 25 | 69 | 55 | 56 | 12 | 269 | |
| Kelly E. Leon | 12 | 188 | 47 | 47 | 16 | 303 |
All Works
Loading papers...